2014), there is mixed literature regarding the degree to which OSA is causative, and whether OSA in the mild‐to‐moderate range, specifically, is associated with developing later cardiometabolic dysfunction (Peppard et al. 2000; Reichmuth et al. 2005; O'Connor et al. 2009; Cano‐Pumarega et al. 2011). Importantly, a recent meta‐analysis concluded that CPAP therapy does not significantly alter lipid levels, insulin resistance, inflammatory markers, or the proportion of patients with the metabolic syndrome (Jullian‐Desayes et al. 2015). The gene discussed is INS; the disease is obstructive sleep apnea syndrome.